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Abstract (250 words) 
Aims 
Carotid sinus hypersensitivity (CSH) is arbitrarily defined as ≥3 seconds asystole or 
vasodepression of ≥50 mmHg in response to carotid sinus massage (CSM). Using this 
definition, 39% of older people meet the criteria for CSH. It has been suggested that current 
criteria are too sensitive. Krediet et al and Kerr et al have proposed modified criteria. This 
population based study aimed to compare the prevalence of CSH defined according to 
standard, Krediet and Kerr criteria, and to establish if CSH defined according these criteria is 
associated with all-cause mortality.  
Methods 
272 community-dwelling people aged ≥65 were recruited at random. CSM was performed 
for five seconds in supine and head-up positions. Heart rate and blood pressure response 
were recorded using an ECG and photoplethysmography. Cox regression analysis was used 
to examine the association between each definition of CSH and all-cause mortality. 
Results:  
Prevalence of CSH defined according to standard, Krediet and Kerr criteria was 39%, 52% 
and 10% respectively. Seventy-one participants died over a mean follow-up of 8.6 years (SD 
2.1). CSH defined according to standard and Krediet criteria was not associated with 
survival. CSH defined according to Kerr criteria was associated with all-cause mortality 
independent of age and sex [HR 2.023 (95% CI 1.131, 3.618) P=0.018)]. This remained 
significant after adjusting for cardiovascular risk factors [HR 2.174 (1.075, 3.900) P= 0.009].  
Conclusions: 
CSH defined according to Kerr criteria is associated with increased mortality. This raises an 
interesting question as to the suitability of the current criteria used to define CSH.  
 
 
Key words 
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Condensed Abstract  
Current criteria for CSH may be too sensitive. Kerr and Krediet proposed modified criteria.  
Community prevalence of CSH defined according to standard, Krediet and Kerr criteria was 
39%, 52% and 10% respectively. Only CSH defined according to Kerr criteria was 
associated with increased all-cause mortality independent of age and cardiovascular risk 
factors.  
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What’s New? 
This is the first study to our knowledge to show an association between CSH and survival. 
We demonstrated that CSH characterised according to criteria, defined according to cut-offs 
derived from the normal response to CSM in older people, is associated with increased 
mortality.  
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Introduction 
Carotid sinus hypersensitivity (CSH) is currently defined as ≥3 seconds asystole, and / or 
≥50 mmHg drop in systolic blood pressure in response to carotid sinus massage1. When it 
occurs in conjunction with syncope or presyncope it is called Carotid Sinus Syndrome 
(CSS). Although these criteria are widely accepted it has been suggested that current criteria 
are too sensitive, particularly in older people2. Kerr et al found that 39% of community 
dwelling adults aged ≥65 years have CSH defined according to these criteria and CSH was 
present in 35% of asymptomatic individuals3. The group reported the 95th percentile for 
carotid sinus massage response was 7.3 seconds asystole and a 77 mmHg drop in systolic 
blood pressure. Based on these data and data from Menozzi et al4 and Brignole et al5,  
Krediet et al suggested that current criteria are over sensitive and proposed future studies 
evaluate modified criteria such that CSM is positive if it triggers an asystole >6 seconds or a 
fall in mean arterial pressure below 60 mmHg for >6 seconds 2. 
 
CSH is associated with significant morbidity including falls, fractured neck of femur and 
head injury 6,7, 8. Surprisingly, despite the significant association between CSH and injury, 
studies to date have failed to show an association between CSH and mortality9, 10. The 
uncertain specificity of current CSH criteria may account for the failure of studies to identify 
an association between CSH and mortality.  
 
This study compared the prevalence of CSH in a community cohort defined according to 
standard criteria, the Krediet criteria and criteria derived from the 95th percentile for response 
to CSM; the Kerr criteria. Secondly, we aim to establish if CSH defined according to 
standard criteria or modified criteria is associated with ten-year all-cause mortality in a 
cohort for whom CSH status is known for all participants.  
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Methods 
Between April 2002 and October 2003, 375 community-dwelling people age 65 and older 
took part in the first phase of a longitudinal study examining the prevalence and clinical 
associations of carotid sinus hypersensitivity (CSH). Participants were recruited at random 
from a single general practice (GP) in the North of England. Persons living in residential or 
nursing care were excluded. Full details of recruitment have been previously described 11.  
 
Carotid Sinus Massage 
All assessments were carried out in a temporary community clinic based close to the 
participants’ general practitioner. Carotid sinus massage (CSM) was performed in consenting 
participants without contraindication. Contraindications included myocardial infarction, 
stroke or transient ischemic attack in the preceding 3 months, history of significant carotid 
stenosis, carotid bruit or clinical suspicion of carotid stenosis.  
 
Subjects rested supine for five minutes before CSM. CSM was performed by the same doctor 
(SJK) in every case. The point of maximum pulsation over the carotid artery, between the 
angle of the mandible and thyroid cartilage was identified. Firm longitudinal massage was 
applied for five seconds. A three-lead ECG was used to monitor cardiac response to the test. 
Continuous beat-to-beat blood pressure was recorded from the hand using digital 
photoplethysmography (Portapress, TNO- Biomedical, Amsterdam).  The subject’s hand was 
supported at heart level throughout all measurements. 
 
CSM was stopped before five seconds if >3 seconds asystole was recorded. CSM was first 
performed on the right hand side in the supine position followed by the left hand side in the 
supine position. Participants were then tilted to the 70-degree head-up tilt position and CSM 
repeated on the right hand side followed by the left hand side.  One minutes rest was allowed 
between each period of massage. The longest RR interval post-CSM and greatest 
vasodepression post-CSM were used to calculate response to CSM.  
Definitions of CSH 
Three definitions of CSH are evaluated:  
1. Standard Criteria 
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A pause in heart rate of ≥3 seconds in response to CSM and /or vasodepression of  ≥ 
50 mmHg drop in systolic blood pressure or both of the above.  
2. Krediet Criteria 
A pause in heart rate of  ≥6 seconds in response to CSM and / or a fall in mean 
arterial pressure to a value <60 mmHg for ≥6 seconds.  
3. Kerr Criteria 
A pause in heart rate in response to CSM >95th percentile of the population response 
(7.3s asystole), and / or vasodepression in response to CSM >95th percentile of the 
population response (>77 mmHg fall in systolic blood pressure), or both. 
Clinical Assessment 
Past medical history was obtained by direct interview of all subjects. Particular attention was 
paid to the presence or absence of cardiovascular disease and risk factors. If participants 
were unsure of their past medical history, GP medical notes were reviewed. Ischemic heart 
disease was defined as a clinical history of angina or myocardial infarction.  
 
Participants were asked to bring a list of all medications they were taking with them to the 
assessment. A composite variable, “use of Cardioactive medication”, was defined as using 
antihypertensive medication, diuretic medication, antianginals, or antiarrhythmics.  
 
Height and weight were recorded and body mass index calculated. Presence or absence of 
signs of cardiac failure was noted.  
 
Participants were fitted with a twenty-four hour ambulatory blood pressure monitor (ABPM) 
(Spacelabs 90207 – Spacelabs Medical Inc, Redmond, Washington USA). An appropriate 
sized cuff was fitted to the non-dominant arm. Subjects were instructed to relax their arm 
when the cuff was inflating. Monitors were programmed to take a BP recording every 30 
minutes during the day (7 am to 10 pm) and every hour overnight (10 pm to 7 am). Mean 
systolic and diastolic blood pressure were calculated for the 24 hour period, daytime and 
night-time.  
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Survival Data 
Participants’ GP electronic medical records were reviewed in September 2012 to identify if 
participants were alive or their date of death. If participants were no longer registered with 
the GP, the National Register of Births, Deaths and Marriages ending September 2012 was 
reviewed to confirm if participants had died and verify their date of death.  
Ethical Approval 
Ethical approval was granted by local research and ethics committees. Written informed 
consent was obtained from all participants.  
Statistics 
All data were analysed using Statistical Package for Social Science (SPSS) version 19. For 
all tests the level of statistical significance was set at <0.05.  
 
Normally distributed continuous data is shown as mean and standard deviation and 
differences between 2 groups compared using Student’s t test. Differences between 3 or 
more groups are compared using an ANOVA with post-hoc Bonferroni correction. Non-
parametric continuous data is shown as median and interquartile range and group differences 
compared using Mann Whitney-U test. Categorical data are shown as percentages and 
compared using Chi square or Fishers exact tests as appropriate.  
 
Time to event is defined as time between date of carotid sinus massage and death or end of 
the study; 1st October 2012. Risk factors associated with mortality were analysed using Cox 
regression analysis initially controlling only for age and sex. Subsequent models adjusted for 
relevant covariates.  
Results 
Of the 375 individuals participating in the study, 35 refused consent for CSM and 68 had a 
contraindication to CSM. Thus, 272 participants underwent CSM. Participants undergoing 
CSM were significantly younger than participants not undergoing CSM [Median age 72 v. 
76 years respectively, P=<0.001], had significantly lower burden of ischemic heart disease 
[21% v. 50%, P<0.001] and were less likely to be taking cardioactive medications [46% v. 
96%, P<0.001].  
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Prevalence of CSH 
As previously reported, of the 272 participants who underwent CSM, 106 participants 
(38.9%) had CSH defined using conventional diagnostic criteria11. One hundred and forty-
one participants (51.8%) had CSH defined according to Krediet criteria and 28 (10.3%) had 
CSH defined according to Kerr criteria. Table 1 shows the prevalence of CSH subtypes 
according to each of these criteria.  
 
The high prevalence of participants meeting the Krediet criteria resulted from the large 
number of individuals meeting the Krediet criteria for vasodepression (Table 1). Figure 1 
compares baseline mean arterial pressure (MAP) for participants according to CSH criteria 
met. Participants meeting the Krediet criteria but not the standard criteria for CSH had 
significantly lower mean arterial BP at baseline (figure 1).  
 
The clinical characteristics of participants according to the presence or absence of CSH 
defined using the three different criteria are shown in Table 2. Regardless of the criteria used 
to define CSH, participants with CSH were older. In addition, participants with CSH defined 
by standard and Kerr criteria were more likely to be male.  
 
Twenty-two patients reported syncope or presyncope during CSM. Table 3 shows the 
proportion of participants reporting symptoms according to CSH status defined by the 3 sets 
of criteria. All 3 sets of criteria were significantly associated with syncope during CSM 
(P<0.001). Only standard and Kerr criteria were associated with presyncope.  
Survival 
Of the 272 participants consenting to CSM, 71 had died at the end of follow-up; mean 
follow-up interval 8.6 years (SD 2.1). When conventional criteria were used to define CSH, 
rates of death in the CSH group were higher compared to the group without CSH but this did 
not differ significantly [32% v 22% respectively, P=0.073]. Mortality was significantly 
greater in the group with CSH defined according to the Krediet criteria compared to those 
without CSH [33% v. 19% respectively, P=0.009]. Use of the Kerr criteria revealed the most 
significant difference in mortality between those with and without CSH [53% versus 23% 
respectively, P<0.001].  
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Cox regression analysis was used to examine if CSH was associated with all-cause mortality. 
Three models were developed. Model 1 adjusted for age and sex. Model 2 made additional 
adjustments for cardiovascular factors associated with CSH and known to influence 
mortality including: body mass index, smoking history (pack years), history of hypertension, 
diabetes, ischemic heart disease and congestive cardiac failure. Finally, in model 3, use of 
cardioactive medication was added to the model.   
 
CSH defined according to conventional criteria and Krediet criteria was not associated with 
survival after adjusting for age and sex. CSH defined according to Kerr criteria was, 
however, independently associated with mortality [HR 2.023 (95% CI 1.131, 3.618) 
P=0.018)] (Table 4). CSH defined according to Kerr criteria remained a significant 
independent predictor of mortality after adjusting for cardiovascular risk factors [HR 2.174 
(95% CI 1.075, 3.900) P= 0.009]. Further adjustment for use of cardioactive medication did 
not substantially attenuate the model [HR 2.154 (95% CI 1.198, 3.873) P=0.010] (Table 4). 
Thus, in all three models, CSH defined according to Kerr Criteria was a significant 
independent predictor of all-cause mortality at ten-year follow-up. In addition, age and male 
gender were independently associated with increased all-cause mortality. Mortality 
decreased with increasing body mass index.  
Survival and Symptoms during CSM 
To examine if symptoms during CSM were important predictors of mortality, cox regression 
analysis was repeated comparing participants with CSH and syncope or presyncope during 
CSM to participants who were asymptomatic. There were no associations between survival 
and symptoms in association with CSH defined by any of the criteria (Table 5).  
 
Discussion 
In this study, we have shown the prevalence of CSH defined by standard, Krediet and Kerr 
criteria is 39%, 52% and 10% respectively. The Krediet criteria were developed due to 
concerns that standard criteria are insufficiently strict. It is therefore surprising that 
prevalence of CSH is higher when Krediet criteria are applied compared applying the 
standard criteria to diagnose CSH. Review of baseline BP revealed that participants meeting 
the Krediet, but not the standard criteria, had a significantly lower baseline MAP. Blood 
pressure in these participants therefore fell below a MAP of 60mmHg without the drop in 
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systolic blood pressure reaching 50 mmHg as stipulated by conventional criteria. 
Conversely, in a small number of participants with significantly higher baseline MAP, 
systolic BP fell by more than 50mmHg without meeting a MAP of 60mmHg or below.   
 
Krediet et al developed their modified criteria in an attempt to strengthen the association 
between CSH and symptoms. Interestingly, all 3definitions of CSH were significantly 
associated with syncope during the test but only standard and Kerr criteria associated with 
presyncope. The positive predictive value for syncope and presyncope during the test was 
greatest for the Kerr criteria and lowest for the Krediet criteria suggesting the Krediet criteria 
are not superior to standard criteria in terms of association with symptoms. 
 
Krediet et al defined vasodepressive CSH as a fall below a MAP of 60mmHg for 6 seconds 
in response to CSM based on clinicopathological reasoning. They argued that when the heart 
stops beating, MAP starts to decline rapidly and reaches a level below 60 mmHg in 3–5 
seconds2. Falls in systemic pressure below the lower limit of cerebral auto-regulation result 
in cerebral hypoperfusion12. The time span from the start of critical cerebral hypoperfusion to 
loss of consciousness is known as ‘cerebral ischemic anoxia reserve time’. The 6 second 
duration of hypotension in response to CSM suggested by Krediet et al is based on studies 
conducted in young men that have shown critical ischemic anoxic reserve time of 5-8 
seconds13.  It is, therefore, interesting that although 139 (51%) participants had a MAP of 
≤60 for ≥6 seconds only 19 of these participants (13%) reported presyncope or syncope 
during CSM.  
 
Traditional criteria stipulate a relative change in blood pressure whereas the Krediet criteria 
require a fall in MAP below a fixed value; 60mmHg. As discussed, participants with a lower 
MAP prior to CSM, only require small decreases in blood pressure in order to meet the 
Krediet criteria for CSH. Conversely, in individuals with chronic hypertension, in whom the 
cerebral autoregulatory curve has shifted to the right, large drops in BP, enough to cause 
cerebral hypoperfusion may occur at a MAP above 60 mmHg. Traditional criteria and Kerr 
criteria for CSH have the advantage that the required change in BP is relative to baseline 
blood pressure.  
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CSH defined according to the Kerr criteria, derived from the normal range of responses to 
CSM among community-dwelling older people, is associated with increased mortality. This 
is the first study to demonstrate an association between CSH and mortality. The association 
was independent of age, hypertension and history of ischemic heart disease, suggesting the 
association between CSH and mortality is not merely a result of the link between CSH and 
cardiovascular disease and raises interesting questions about the monitoring and management 
of patients with CSH meeting the Kerr criteria.  
 
CSH defined according to standard criteria and Krediet was not associated with survival. 
This is in keeping with two previous studies9,10. Hampton et al examined mortality among 
1504 patients with CSH identified from a single syncope centre. Standardised mortality rates 
(SMRs) were compared with regional age matched SMR data from the office of national 
statistics. There was no difference between CSH patients (CSH defined according to 
standard criteria) and the general population in SMRs for all-causes, or for cerebrovascular 
or cardiovascular deaths9. In a similar study, Brignole et al followed-up 262 patients with a 
history of syncope or presyncope in whom CSM resulted in CSH and reproduced their 
symptoms. Mortality over a 6-year follow-up was compared to mortality among 55 patients 
with unexplained syncope and SMR of the Italian general population with similar age and 
sex distribution. Mortality rates in all three groups were similar10.  
 
Both the Hampton et al and the Brignole et al studies recruited symptomatic participants with 
CSH from syncope clinics and compared to SMR9,10. Kerr et al, however, found over 25% of 
individuals with CSH defined according to standard criteria had no prior history of syncope, 
presyncope or dizziness and the majority of symptomatic patients with CSH had not been 
referred to a specialist clinic11. The high prevalence of CSH (defined according to standard 
criteria) among asymptomatic older individuals means it is likely the control populations 
from which the SMR were derived included a significant proportion of asymptomatic 
patients with undiagnosed CSH. Our study was the first study examining the association 
between CSH and mortality among a community cohort in whom CSH status of all 
participants had been assessed and documented.  
 
Current guidelines for implantation of pacemakers for cardioinhibitory CSH stipulate that 
CSM should be associated with reproduction of symptoms of presyncope or syncope1. In this 
study, CSH according to Kerr criteria, but not symptoms were associated with mortality. 
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This raises interesting questions as to whether pacing should be considered for asymptomatic 
individuals meeting the Kerr criteria. Even though it is recommended by current guidelines, 
previous clinical trials evaluating pacing for the treatment of cardioinhibitory CSS have 
failed to reliably show benefit with pacing. Although there are several possible explanations 
for this, it may reflect the lack of specificity of standard criteria.   
 
A number of limitations to this study should be acknowledged. Firstly, participants 
undergoing CSM were significantly younger and less likely to have cardiovascular disease 
than the participants who did not undergo CSM. This is an inevitable consequence of the 
contraindications to CSM (recent stroke, myocardial infarction, persistent arrhythmia). The 
prevalence of CSH increases with age and CSH is associated with hypertension and 
cardiovascular disease. Given that older individuals with a history of cardiovascular disease 
were excluded from the study it is likely that the true prevalence of CSH in the wider 
population may have been underestimated.  
 
This study did not examine cause-specific mortality. Mortality due to CSH may result from 
morbidity associated with related falls and syncope. Approximately one in ten falls are 
associated with injury, including hip fracture, subdural haemorrhage, or soft tissue injury14. 
Of people admitted to hospital with a fall, about 50% are alive at 1 year15. CSH is associated 
with autonomic dysfunction and it has also been suggested that CSH related deaths may be 
due to prolonged asystole or malignant arrhythmias triggered by severe vasodepression9. 
Future studies are needed that examine the association between the Kerr criteria and cause-
specific mortality and to examine the association between CSH defined by Kerr criteria and 
falls and / or syncope.  
 
Larger studies are also needed to compare mortality related to the different subtypes of CSH. 
The small number of individuals with pure cardioinhibitory and mixed CSH, particularly 
when CSH was defined according to Kerr criteria, prohibited comparison of subtypes.  
 
Readers should also note that the favoured protocol for preforming CSM has been modified 
since this study began. In line with guidelines available at the time of the studies inception 
CSM was performed for 5 seconds16, 17. Since 2009, the European Society of Cardiology 
have recommended carotid sinus massage should be performed for 10 seconds18. No 
comparator studies have been conducted to assess the optimum duration of CSM but some 
14 
 
authors suggest longer CSM may be associated with higher rates of syncope. Although this 
has not been proven, increasing duration of CSM may result in increased prevalence of CSH 
and / or CSS.  
 
Summary  
This is the first study to our knowledge to show an association between CSH and survival. 
We demonstrated that CSH characterised according to the Kerr criteria, defined according to 
cut-offs derived from the normal response to CSM in older people, affects 10% of the 
population aged 65 and over and is associated with increased mortality. In addition, it 
showed that over 50% of community-dwelling older people have a response to CSM that 
meets modified criteria for CSH proposed by Krediet et al. These criteria and standard 
criteria were not associated with survival. Future studies should evaluate the prognostic 
value of the 3 definitions of CSH in terms of predicting future falls, syncope and the ability 
of the criteria to identify patients who would benefit from pacing. 
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Figures 
 
Figure 1 Comparison of baseline mean arterial pressure according to CSH criteria met. 
Error bars show 95% confidence intervals. P values are calculated using one way ANOVA 
with Bonferroni correction.  
  
P<0.001
P<0.001
P=0.001
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Tables 
Table 1 Prevalence of CSH and CSH subtypes according to different criteria 
 Standard 
Criteria 
N (%) 
Krediet  
Criteria 
N (%) 
Kerr 
Criteria 
N (%) 
Carotid Sinus Hypersensitivity 106 (39) 141 (52) 28 (10) 
    
 Cardioinhibitory 6  2 6 
 Vasodepressive 42 116 16 
 Mixed 58 23 6 
 
17 
 
Table 2 Demographic and Clinical Characteristics for Participants with and without CSH According to the 3 Different Definitions of CSH 
 Conventional Criteria Krediet Criteria Kerr Criteria  
 No CSH 
N=166 
CSH 
N = 106 
P No CSH 
N=131 
CSH 
N= 141 
P No CSH 
N=244 
CSH 
N=28 
P 
Age [median (IQR)] 71 (67, 76) 73 (69,79) 0.015 70 (67, 75) 74 (69. 78) <0.001 71 (68, 76) 75 (71, 79) 0.013 
Sex [male (%)] 86 (51.8) 68 (64.2) 0.045 67 (51.1)) 87 (61.2) 0.079 133 (54.5) 21 (75.0) 0.038 
BMI 27 (4.0) 26 (3.4) 0.039 27 (3.9) 27 (3.8) 0.657 26.8 (3.9) 26.7 (2.9) 0.866 
Pack years 3 (0, 20) 9 (0, 26) 0.082 2 (0, 20) 10 (0, 25) 0.031 4 (0, 20) 16 (0, 30) 0.075 
Mean Daytime Ambulatory BP          
 Systolic BP [mean (SD)] 134 (15.0) 135 (14.2) 0.481 135 (14.7) 134 (14.1) 0.406 134 (14.7) 132 (14.4) 0.345 
 Diastolic BP [mean (SD)] 75 (9.6) 78 (8.9) 0.006 77.8 (9.3) 75.4 (7.5) 0.021 75.6 (9.6) 77.5 (8.2) 0.345 
          
 N (%) N(%) P N (%) N(%) P N (%) N(%) P 
Ischemic Heart Disease 33 (19.9) 25 (23.6) 0.467 20 (15.3) 38 (30.0) 0.019 52 (21.3) 6 (21.4) 0.989 
Hypertension 53 (31.9) 47 (44.3) 0.038 45 (34.4) 55 (39.0) 0.426 86 (35.2) 14 (50.0) 0.125 
Cardiac Failure 11 (6.6) 10 (9.4) 0.398 9 (6.9) 12 (8.5) 0.613 19 (7.8) 2 (7.1) 1.000 
Diabetes 11 (6.6) 5 (4.7) 0.514 5 (3.8) 11 (7.8) 0.163 15 (6.1) 1 (3.6) 1.000 
Hypercholesterolemia 49 (29.5) 30 (28.3) 0.829 36 (27.5) 43 (30.5) 0.584 71 (29.1) 8 (28.6) 0.954 
Cardioactive Medication 73 (44.0) 51 (48.1) 0.504 53 (40.5) 68 (48.2) 0.365 109 (44.7) 15 (53.6) 0.371 
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Table 3 Proportion of patients with each form of CSH who reported symptoms during 
CSM 
 Standard CSH 
N=106 
n (%) 
Krediet CSH 
N=141 
n (%) 
Kerr CSH 
N=28 
n (%) 
Syncope  17 (16)* 16 (11)* 13 (46)* 
Presyncope 9 (8)*  7 (5) 5 (18)* 
Syncope or Presyncope 22 (20)* 19 (13)* 14 (50)* 
Chi square test used to examine significance of association between criteria and symptoms 
during CSM, *indicates significant associations (P<0.001 in all cases).   
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Table 4 Cox Regression Models. Relative risk of all-cause mortality associated with CSH according to conventional, Krediet and Kerr 
criteria.  
 
 
 
 
 
 Conventional Criteria Krediet Criteria Kerr Criteria 
 HR 95% CI  P HR 95% CI P HR 95% CI P 
Model 1          
CSH 1.286 0.809, 2.046 0.288 1.319 0.799, 2.177 0.280 2.023 1.131, 3.618 0.018 
Age 1.121 1.082, 1.162 <0.001 1.117 1.076, 1.159 <0.001 1.115 1.075, 1.156 <0.001 
Sex 1.792 1.094, 2.934 0.020 1.773 1.081, 2.906 0.023 1.793 1.092, 2.946 0.021 
Model 2          
CSH       2.174 1.212, 3.900 0.009 
Age       1.091 1.048, 1.135 <0.001 
Sex       1.713 1.011, 2.901 0.045 
BMI       0.913 0.851, 0.980 0.012 
Pack Years       1.011 0.999, 1.022 0.061 
Hypertension        1.546 0.951, 2.512 0.079 
Diabetes       1.626 0.720, 3.670 0.242 
IHD       0.931 0.517, 1.676 0.812 
CCF       1.878 0.887, 3.974 0.099 
Model 2          
CSH       2.154 1.198, 3.873 0.010 
Age       1.090 1.048, 1.134 <0.001 
Sex       1.718 1.014, 2.909 0.044 
BMI       0.911 0.848, 0.979 0.011 
Pack Years       1.011 1.000, 1.022 0.060 
Hypertension        1.531 0.941, 2.941 0.087 
Diabetes       1.599 0.706, 3.620 0.260 
IHD       0.868 0.457, 1.651 0.667 
CCF       1.791 0.831, 3.860 0.137 
CV Meds       1.159 0.650, 2.067 0.616 
BMI =body mass index, IHD = ischemic heart disease, CCF= congestive cardiac failure, CV meds = cardioactive medication 
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Table 5 Cox Regression Models. Hazard ratio of all-cause mortality associated with symptomatic CSH defined according to standard criteria, 
Krediet criteria and Kerr criteria. 
 
 
 Conventional Criteria Krediet Criteria Kerr Criteria 
 HR 95% CI  P HR 95% CI P HR 95% CI P 
Model 1          
CSH + Symptoms 1.589 0.760, 3.326 0.219 1.814 0.867, 3.796 0.114 2.021 0.870, 4.695 0.102 
Age 1.124 1.084, 1.165 <0.001 1.123 1.084, 1.165 <0.001 1.125 1.085, 1.166 <0.001 
Sex 1.833 1.120, 3.000 0.016 1.805 1.102, 2.955 0.019 1.783 1.089, 2.918 0.022 
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